Current strategies in the management of hormone refractory prostate cancer

Cancer Treatment Reviews

Volumn 29, Issue 3, 2003, Pages 171-187

  Martel, Cynthia L ^a   Gumerlock, Paul H ^a   Meyers, Frederick J ^a   Lara Jr , Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Clinical trials; Hormone refractory; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; DEXAMETHASONE; DIETHYLSTILBESTROL; DNA; ESTRAMUSTINE; ETIDRONIC ACID; FLUTAMIDE; GONADORELIN AGONIST; HYDROCORTISONE; IFOSFAMIDE; KETOCONAZOLE; MELPHALAN; MITOXANTRONE; PAMIDRONIC ACID; PC SPES; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ALLERGIC REACTION; BIOASSAY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION FUNCTION; DETERIORATION; DISEASE COURSE; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; GENETIC STABILITY; HUMAN; INTENSIVE CARE; MALE; MEDICAL DECISION MAKING; METASTASIS; NAUSEA; PALLIATIVE THERAPY; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; UNITED STATES;

EID: 0038481707     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00090-7     Document Type: Review

References (188)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52(1): 23-47.
2. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26(2): 162-173.
3. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355(9214): 1491-1498.
4. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12(9): 1868-1875.
5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia group B 9182 study. J Clin Oncol 1999; 17(8): 2506-2513.
6. Smaletz O, Scher HI, Kelly WK, Verbel DA, Regan K, Curley T, et al. A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC). Proc Am Soc Clin Oncol 2001; 20: 183a.
7. Small EJ, Halabi S, Picus J, Chen Y, Vogelzang NJ. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583. Proc Am Soc Clin Oncol 2001; 20: 174a.
8. Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs 2001; 61(15): 2177-2192.
9. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46(2): 142-148.
10. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17(11): 3461-3467.
11. Lara Jr PN, Kung HJ, Gumerlock PH, Meyers FJ. Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol 1999; 32(3): 197-208.
12. Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech 2000; 51(5): 456-463.
13. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153(1): 141-148.
14. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74(8): 1258-1262.
15. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157(2): 569-574.
16. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994; 86(12): 926-933.
17. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154(2, Pt 1): 414-421.
18. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, de Vere White RW. Complex functions of mutant p53 alleles, from human prostate cancer. Prostate 2002; 51(1): 59-72.
19. Stearns ME, Wang M. Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol. Oncol Res 1994; 6(4-5): 195-201.
20. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7(7): 1932-1936.
21. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997; 31(1): 1-6.
22. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001; 20(46): 6718-6723.
23. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55(14): 3068-3072.
24. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21): 1393-1398.
25. Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999; 187(2): 237-241.
26. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164(6): 1992-1995.
27. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9(4): 401-406.
28. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2(2): 277-285.
29. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2(2): 277-285.
30. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60(4): 944-949.
31. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332(21): 1393-1398.
32. Shi XB, Ma AH, Xia L, Kung HJ, Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62(5): 1496-1502.
33. George DJ, Kantoff PW. Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 1999; 26(2): 303-310, viii.
34. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16(5): 1835-1843.
35. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11(4): 607-615.
36. Akimoto S, Inomiya H, Akakura K, Shimazaki J, Ito H. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. Jpn J Clin Oncol 1997; 27(4): 258-262.
37. Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71(11): 3594-3600.
38. Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 1992; 70(12): 2870-2878.
39. Akimoto S, Masai M, Akakura K, Shimazaki J. Marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995; 27(3): 207-212.
40. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia group B studies. Clin Cancer Res 1999; 5(4): 831-837.
41. Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995; 13(12): 2944-2953.
42. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol 2001; 19(5): 1304-1311.
43. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756-1764.
44. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. J Urol 2000; 163(5): 1481-1485.
45. Lara Jr PN, Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest 1999; 17(2): 137-144.
46. Fowler Jr JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126(3): 372-375.
47. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11(11): 2167-2172.
48. Chao D, Harland SJ. The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer. Eur Urol 1997; 31(1): 7-10.
49. Manni A, Bartholomew M, Caplan R, Boucher A, Sariten R, Lipton A, et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988; 6(9): 1456-1466.
50. Fowler Jr JE, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154(2, Pt 1): 448-453.
51. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8): 2928-2938.
52. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 2000; 37(2): 218-222.
53. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1): 149-153.
54. Sinibaldi V, Carducci M, Abeloff M, Eisenberger M. Experience with casodex in patients in patients with stage D3 prostate cancer. Proc Am Soc Clin Oncol 1997; 16: 313a.
55. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149(3): 607-609.
56. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies. Incidence and clinical significance. Drug Safety 2000; 23(5): 381-390.
57. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 1994; 86(3): 222-227.
58. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58(2, Suppl. 1): 108-113.
59. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, et al. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999; 5(9): 2366-2373.
60. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000; 88(4): 825-834.
61. Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C. A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am J Clin Oncol 1989; 12(4): 358-360.
62. Samojlik E, Lippman AJ, Kirschner MA, Ertel NH, Park Y, Szmal E. Medical adrenalectomy for advanced prostatic cancer: clinical and hormonal effects. Am J Clin Oncol 1988; 11(5): 579-585.
63. Sartor O, Weinberger M, Moore A, Li A, Figg WD. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 1998; 52(2): 252-256.
64. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76(1): 96-100.
65. Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 1998; 5(1): 44-47.
66. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000; 89(12): 2570-2576.
67. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15(1): 382-388.
68. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19(1): 62-71.
69. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339(12): 785-791.
70. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000; 18(21): 3595-3603.
71. The FDA safety information and adverse event reporting program. 2002 safety information summaries; 2002.
72. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan. VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1989; 7(8): 1093-1098.
73. Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer. Can J Surg 1989; 32(5): 349-352.
74. Eichenberger T, Trachtenberg J. Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer. Am J Clin Oncol 1988; 11(Suppl. 2): S104-S107.
75. Gerber GS, Chodak GW. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol 1990; 144(5): 1177-1179.
76. Jubelirer SJ, Hogan T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J Urol 1989; 142(1): 89-91.
77. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157(4): 1204-1207.
78. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997; 80(9): 1755-1759.
79. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001; 31(1): 62-68.
80. Smith Jr JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141(1): 85-87.
81. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165(1): 136-140.
82. Dearnaley DP, Sydes MR. On behalf of the MRC PR05 collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. Proc Am Soc Clin Oncol 2001; 20: 174a.
83. Ernst DS, Tannock IF, Venner PM, Winquist EW, Reyno L, Walker H, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc Am Soc Clin Oncol 2002; 21: 177a.
84. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345(13): 948-955.
85. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001; 28(2, Suppl. 6): 11-16.
86. Furuya Y, Akakura K, Akimoto S, Ichikawa T, Ito H. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol 1999; 6(4): 187-191.
87. Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibashi K, Ueda T. [Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1993; 84(9): 1681-1684.
88. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33(4): 907-912.
89. Kawakami S, Kawai T, Yamauchi T, Yonese J, Ueda T, Ishibashi K. [Palliative radiotherapy for bone pain in hormone refractory prostate cancer]. Nippon Hinyokika Gakkai Zasshi 1993; 84(10): 1791-1796.
90. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274(5): 420-424.
91. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31(1): 33-40.
92. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25(5): 805-813.
93. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38(4, Suppl. 1): 123-127.
94. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34(11): 1839-1844.
95. Sandeman TF, Budd RS, Martin JJ. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol (R Coll Radiol) 1992; 4(3): 160-164.
96. Roth BJ. Androgen-independent prostate cancer: not so chemorefractory after all. Semin Oncol 1999; 26(6, Suppl. 18): 43-50.
97. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71(3, Suppl.): 1098-1109.
98. Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, et al. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother Pharmacol 1993; 31(5): 363-368.
99. Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. Am J Clin Oncol 1996; 19(4): 368-370.
100. van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, Mickisch GH. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2000; 45(6): 509-512.
101. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994; 74(1): 100-103.
102. Schmid HP, Maibach R, Bernhard J, Hering F, Hanselmann S, Gusset H, et al. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer 1997; 79(9): 1703-1709.
103. Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thurlimann B, et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11(2): 183-188.
104. Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest New Drugs 1998; 16(4): 353-359.
105. Witte RS, Yeap BY, Trump DL. Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial. Invest New Drugs 1994; 12(3): 255-258.
106. Rajagopalan K, Peereboom D, Budd GT, Olencki T, Murthy S, Elson P, et al. Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer. Invest New Drugs 1998; 16(3): 255-258.
107. Atkins JN, Muss HB, Case LD, Richards F, Grote T, McFarland J. Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. Am J Clin Oncol 1996; 19(1): 23-25.
108. Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, et al. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol 1998; 21(2): 171-176.
109. Huan SD, Aitken SE, Stewart DJ. 5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study. Ann Oncol 1994; 5(7): 644-645.
110. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 1993; 72(6): 1965-1968.
111. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000; 11(2): 123-127.
112. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozols RF, et al. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 1995; 13(3): 235-240.
113. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 1996; 14(5): 1617-1625.
114. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999; 22(5): 471-474.
115. Naito S, Ueda T, Kotoh S, Kumazawa J, Itoh K, Sagiyama K, et al. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother Pharmacol 1995; 35(3): 225-229.
116. Fuse H, Muraishi Y, Fujishiro Y, Katayama T. Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. Int Urol Nephrol 1996; 28(1): 79-85.
117. von Roemeling R, Fisher HAG, Horton J. Daily oral cyclophosphamide is effective in hormone refractory prostate cancer: a ph-I/II pilot study. Proc Am Soc Clin Oncol 1992; 11: 213.
118. Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993; 72(5, Pt 1): 625-628.
119. Ukimura O, Kamoi K, Hongo F, Nakao M, Mizutani Y, Nishimura K, et al. Oral administration of dexamethasone in combination with UFT and cyclophosphamide for the treatment of hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 2001; 20: 165b.
120. Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77(6): 1144-1148.
121. Wozniak AJ, Blumenstein BA, Crawford ED, Boileau M, Rivkin SE, Fletcher WS. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Cancer 1993; 71(12): 3975-3978.
122. Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer 1992; 28(2-3): 477-478.
123. Raghavan D, Coorey G, Rosen M, Page J, Farebrother T. Management of hormone-resistant prostate cancer: an Australian trial. Semin Oncol 1996; 23(6, Suppl. 14): 20-23.
124. Otto T, Rembrink K, Goepel M, Krege S, Meyer-Schwiekerath M, Rubben H. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study]. Urologe A 1996; 35(2): 142-145.
125. Kantoff PW, Block C, Letvak L, George M. 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am J Clin Oncol 1993; 16(6): 489-491.
126. Kozloff M, Robin EL, Raminski D, Rao Uppuluri VS, Sylora J, Starr A, et al. A phase II study using mitoxantrone and ketoconazole in hormone resistant metastatic adenocarcinoma of the prostate. Proc Am Soc Clin Oncol 2001; 20: 153b.
127. Stearns ME, Tew KD. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 1988; 89(Pt 3): 331-342.
128. 2 in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2001; 20: 183a.
129. Morote J, Lopez-Pacios MA, Ahmad A, Vila J, De Torres JA. [Treatment of hormone-refractory prostate cancer with estramustine phosphate]. Actas Urol Esp 1991; 15(5): 421-424.
130. Tanaka M, Shiomi K, Hamano S, Suzuki N, Igarashi T, Murakami S, et al. [Effect of estramustine phosphate on hormone refractory prostate cancer]. Hinyokika Kiyo 1997; 43(3): 245-250.
131. Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 1997; 157(3): 929-934.
132. de Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology 1988; 31(4): 312-317.
133. Loening SA, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, et al. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983; 129(5): 1001-1006.
134. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50(5): 754-758.
135. Sumiyoshi Y, Hashine K, Nakatsuzi H, Yamashita Y, Karashima T. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Int J Urol 2000; 7(7): 243-247.
136. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12(10): 2005-2012.
137. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50(3): 401-406.
138. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, et al. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate 2001; 46(4): 257-261.
139. Soloway MS, Dekernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981; 125(5): 664-667.
140. Awakura Y, Yamamoto M, Fukuzawa S, Itoh N, Nonomura M, Fukuyama T. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer]. Hinyokika Kiyo 2000; 46(7): 449-452.
141. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992; 10(11): 1754-1761.
142. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992; 147(3, Pt 2): 931-934.
143. Sella A, Flex D, Konichezky M, Sulkes A, Baniel J. Combination chemotherapy following adrenal suppression in androgen-independent prostate cancer. Eur Urol 2000; 38(3): 255-258.
144. Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero JM, Arcusa A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 1998; 37(2): 187-191.
145. Pienta KJ, Olson KB. Treatment of metastatic hormone refractory prostate cancer with estramustine (emcyt) and vinorelbine. Proc Am Soc Clin Oncol 2001; 20: 168b.
146. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997; 20(4): 383-386.
147. Hudes G, Ross E, Roth B, Balshem A, Loehrer PJ, Ramsey H, et al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate. Proc Am Soc Clin Oncol 2002; 21: 177a.
148. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma-of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72(8): 2457-2460.
149. Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89(2): 431-436.
150. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 1995; 22(5, Suppl. 12): 41-45.
151. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15(9): 3156-3163.
152. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001; 58(1): 59-64.
153. Athanasiadis A, Tsavdaridis D, Athanassiades I, Pergantas N, Roussos G, Rigatos SK, et al. Paclitaxel (P) and estramustine phosphate (EP) in patients with hormone refractory prostate cancer (HRPC) - a phase II study. Proc Am Soc Clin Oncol 2001; 20:189a.
154. Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, et al. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer 2001; 91(11): 2039-2045.
155. Vaishampayan UN, Fontana JA, Hussain M. An active regimen of weekly estramustine and paclitaxel in metastatic androgen independent (AI) prostate cancer. Proc Am Soc Clin Oncol 2001; 20: 188a.
156. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17(6): 1664-1671.
157. Friedland D, Cohen J, Miller Jr R, Voloshin M, Gluckman R, Lembersky B, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumour effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26(5, Suppl. 17): 19-23.
158. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26(5, Suppl. 17): 14-18.
159. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001; 28(4, Suppl. 15): 8-15.
160. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel (TAXOTERE) in hormone refractory metastatic prostate cancer (HRPC). Proc Am Soc Clin Oncol 2000; 19: 348a.
161. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17(3): 958-967.
162. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10(1): 33-38.
163. Copur MS, Tarantolo SR, Hauke R, Ledakis P, Lynch JC, Bolton M, et al. Weekly estramustine (E) taxotere (T) and dexamethasone (D) in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2000; 19: 347a.
164. Kosty MP, Ferreira A, Bryntesen T, Grossman J. Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc Am Soc Clin Oncol 2000; 19: 365a.
165. Petrylak DP, Shelton GB, England-Owen C, Pfaff C, Bagliella E, Diuleo, R, et al. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (pts) with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2000; 19: 334a.
166. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of Cancer and Leukemia Group B CALGB 9780. J Clin Oncol 2001; 19(9): 2509-2516.
167. Sinibaldi VJ, Eisenberger MA. Preliminary evaluation of docetaxel plus 1-day estramustine in the treatment of prostate cancer. Advances in Prostate Cancer 2000; 4: 8-10.
168. Sitka CM, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001; 28(4, Suppl. 15): 16-21.
169. Casciano R, Petrylak D, Neugut AI, Doyle J, Casciano J, Arikian S, et al. Systematic review of chemotherapy efficacy from controlled trials in hormone-refractory prostate cancer (HRPC) patients. Proc Am Soc Clin Oncol 2001; 20: 169b.
170. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 1999; 26(5, Suppl. 17): 55-60.
171. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 2002; 16(6, Suppl. 6): 63-72.
172. Hwang LC, Fein S, Levitsky H, Nelson WG. Prostate cancer vaccines: current status. Semin Oncol 1999; 26(2): 192-201.
173. Lara Jr PN, Meyers FJ, Gray CR, Gandour Edwards R, Gumerlock PH, Kauderer C, et al. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the California Cancer Consortium screening trial. Cancer 2002; 94: 2584-2589.
174. Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2(8): 1289-1297.
175. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, et al. Radioimmunotherapy with (111)In/(90)Y-2ITBAD-m170 for metastatic prostate cancer. Clin Cancer Res 2001; 7(6): 1561-1568.
176. Schellhammer P, Small EJ, Higano CS, Neumunaitis J, Peshwa M, Jones L, et al. Autologous dendritic cells pulsed with prostatic acid phosphatase (APC8015) for hormone refractory prostate cancer: a phase III randomized, double blind, placebo controlled trial. Proc Am Soc Clin Oncol 2002; 21: 183a.
177. Li Y, Chinni SR, Senderowicz AM, Sarkar FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 2000; 17(4): 755-759.
178. Ryan CW, Stadler WM, Vogelzang NJ. Docetaxel and exisulind in hormone-refractory prostate cancer. Semin Oncol 2001; 28(4, Suppl. 15): 56-61.
179. Goluboff ET, Prager D, Rukstalis D, Giantonio, B, Madorsky M, Barken I, et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001; 166(3): 882-886.
180. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55(11): 2325-2333.
181. Carducci MA, Nelson JB, Padley RJ, Janus T, Hippensteel. R. The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo-controlled trial. Proc Am Soc Clin Oncol 2001; 20: 174a.
182. Logothetis CJ, Yang H, Daliani D, Millikan RE, Tu S, Pagliaro L, et al. Dose dependent inhibition of 20S proteasome results in serum Il-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc Am Soc Clin Oncol 2001; 20: 186a.
183. Gumerlock PH, Lara PN, Gandara DR. Docetaxel followed by PS-341 results in phosphorylation and stabilization of p27 and increased response in non small cell carcinoma (NSCLC). Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2001; 157.
184. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7(12): 3920-3927.
185. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001; 7(7): 1888-1893.
186. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001; 28(4, Suppl. 15): 62-66.
187. Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, et al. Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2001; 20:174a.
188. Heath EI, Grochow LB. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000; 59(5): 1043-1055.